Amylyx Pharmaceuticals, Inc.
AMLX
$13.94
-$0.11-0.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 23.05% | 266.17% | |||
| Gross Profit | -23.05% | -274.91% | |||
| SG&A Expenses | -0.28% | -8.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.37% | -5.47% | |||
| Operating Income | -13.37% | 7.01% | |||
| Income Before Tax | -15.42% | 5.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.42% | 4.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.42% | 4.37% | |||
| EBIT | -13.37% | 7.01% | |||
| EBITDA | -13.46% | 7.03% | |||
| EPS Basic | -10.95% | 23.46% | |||
| Normalized Basic EPS | -10.96% | 40.16% | |||
| EPS Diluted | -10.95% | 23.46% | |||
| Normalized Diluted EPS | -10.96% | 40.16% | |||
| Average Basic Shares Outstanding | 4.02% | 24.93% | |||
| Average Diluted Shares Outstanding | 4.02% | 24.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||